Kenya Anti Aging Therapeutics Market Analysis

Kenya Anti-Aging Therapeutics Market Executive Summary

The Kenya anti-aging therapeutics market size is at around $0 Mn in 2022 and is projected to reach $2 Mn in 2030, exhibiting a CAGR of 17.63% during the forecast period. In the budget for 2022–23, the Kenyan government has set aside $1.13 Bn to pay for healthcare services. The ability of health care professionals to offer high-quality services supported by adequately stocked and equipped healthcare facilities is dependent on their availability, accessibility, and capacity. $0.48 Bn of the $1.13 Bn budgeted for health care will go toward actions and programs aimed at achieving universal coverage. The cost of COVID-19 vaccines and associated expenses has been budgeted at $54 Mn, with $32 Mn set aside for free maternity healthcare. $14 Mn will be allocated for medical coverage for the elderly and seriously disabled members of society, while $40 Mn will be spent on managed equipment services.

A range of goods and services are included in Kenya's anti-aging therapeutics with the goal of enhancing older people' wellness and health. A medical procedure called hormone replacement therapy (HRT) includes giving older people extra amounts of hormones like estrogen and testosterone. HRT may be used to address male hypogonadism or female menopause. Many childhood, infectious, and preventable illnesses have been eradicated as a result of improved healthcare and pharmaceutical knowledge; however, as lifespans rise, we are now seeing the effects of aging disorders. Many people's thoughts have been directed toward dementia and aging-related brain decline as a result of headline-grabbing indications like Alzheimer's disease. Thus, the consideration of therapeutics must begin with factors linked to neurological function and associated behaviors.

One of the most common anti-aging medications today, rapamycin modulates proteostasis to at least partially slow down the aging process. At the organismal level, the proteostatic systems of various cells and tissues are intricately intertwined. The non-autonomous control of particular proteostatic pathways by cells and organs has now been proven in mice and invertebrates. Exosomes, which can transport chaperones and other proteins between cells, are liquid components that may be used as a channel for interorgan communication that regulates proteostasis. One peripheral organ can potentially have an effect on systemic aging, according to studies done on mice in Kenya. For instance, activating 4E-BP1 (a downstream effector of mTORCl) only in muscle is enough to encourage good aging in a variety of tissues. Through its impacts on metabolic function, metformin has been suggested as a general anti-aging therapeutic. Diabetes, a disease linked to faster aging, is treated with it. The drug metformin has been shown to improve the health and lifespan of mice, and there are epidemiological correlations between its use in treating elderly people with type 2 diabetes and greater longevity.

Market Dynamics

Market Growth Drivers Analysis

The middle class in Kenya is expanding, and with it, so is the desire for goods related to health and wellness. The Kenya anti-aging therapeutics market is likely to expand as people become more health conscious and look for methods to enhance their general well-being. The life expectancy in Kenya has risen recently as a result of advancements in healthcare and medical technology. In order to improve their health and quality of life, a greater proportion of older adults may be interested in anti-aging therapeutics.  Chronic conditions like diabetes, heart disease, and cancer are becoming more prevalent in Kenya. Therapeutics against aging may aid in the treatment or prevention of some of these illnesses, increasing demand for these goods.

Market Restraints

Despite advancements in Kenya's healthcare system, access to services is still restricted, particularly in rural regions. A lack of access to the medical services needed to diagnose and treat age-related health conditions may limit the growth of Kenya anti-aging therapeutics. Since most people in Kenya live on poor incomes, the cost of anti-aging therapeutics may prevent them from being widely used there. Anti-aging therapeutics are presently not subject to any specific regulatory framework in Kenya. If there is no obvious path for regulatory approval, manufacturers might be reluctant to invest in research and development, which could limit the market availability of these commodities.

Competitive Landscape

Key Players

• Benmed Pharmaceuticals (KEN)
• Beta Healthcare (KEN)
• Biodeal Laboratories (KEN)
• Comet Healthcare (KEN)
• Cosmos (KEN)
• Cambrian Biopharma
• CytoMed Therapeutics
• Gero
• Rejuvenate Bio
• Rejenevie Therapeutics
• MyMD Pharmaceuticals
• Intervene Immune
• CohBar
• Alkahest

Healthcare Policies and Regulatory Landscape

The Pharmacy and Poisons Board (PPB) is Kenya's regulating body in charge of monitoring pharmaceuticals, including anti-aging medications.  The PPB is a statutory organization under the Ministry of Health, and its main responsibility is to oversee and control the manufacture, distribution, and sale of pharmaceutical goods in Kenya as well as their importation and export. Prior to being marketed and sold in the nation, pharmaceutical goods, including anti-aging medications, must be registered and licensed with the PPB. Pre-clinical and clinical trials are used to thoroughly assess the product's quality, safety, and efficacy as part of the registration procedure. In order to verify compliance with GMPs (good manufacturing practices) and GDPs (good distribution practices), the PPB also has the power to examine manufacturing facilities and distribution networks. Additionally, the PPB is in charge of overseeing and upholding Kenya's pharmaceutical laws. If a pharmaceutical product violates regulatory requirements or there is proof of a safety concern, the board has the power to stop or revoke its registration.